Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05378100 · ClinicalTrials.gov registry record · Phase 2
Ketamine for Multiple Sclerosis Fatigue
A Phase 2 study of Multiple Sclerosis Fatigue, sponsored by Johns Hopkins University.
- Active
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT05378100: Active Phase 2 study of Multiple Sclerosis Fatigue, sponsored by Johns Hopkins University.
NCT05378100 is a Phase 2 study of Multiple Sclerosis Fatigue that is active but no longer recruiting, run by Johns Hopkins University. The registered enrollment target is 110 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05378100, a Phase 2 study of Multiple Sclerosis Fatigue, is active but no longer recruiting, sponsored by Johns Hopkins University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study is a single-center, phase II, randomized, double-blind, parallel-group, active-placebo-controlled trial of intravenous low-dose ketamine in patients with MS fatigue.
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG Midazolam
Study Locations (1)
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05378100
The ClinicalTrials.gov registry entry for NCT05378100 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis Fatigue appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT05378100 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05378100 about?
NCT05378100 is a clinical study titled "Ketamine for Multiple Sclerosis Fatigue". The proposed study is a single-center, phase II, randomized, double-blind, parallel-group, active-placebo-controlled trial of intravenous low-dose ketamine in patients with MS fatigue.
What is the current status of trial NCT05378100?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2023-01-01. Estimated completion is 2026-10-01.
What conditions does trial NCT05378100 study?
This clinical trial studies the following conditions: Multiple Sclerosis Fatigue.
What interventions are being tested in trial NCT05378100?
The interventions under investigation include: Ketamine (DRUG), Midazolam (DRUG).
Who is sponsoring clinical trial NCT05378100?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05378100 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis Fatigue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.